HighTide Completes Enrollment in US Phase II Trial of NASH Candidate

HighTide Therapeutics, a Shenzhen-Maryland biopharma, reported it has completed enrollment in a US Phase IIa trial of its novel NASH treatment. The double-blind, dose-ranging trial will assess the efficacy and safety of HTD1801 in adults with NASH and type 2 diabetes. HighTide develops novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders. HTD1801, the company’s lead candidate, is a first-in-class new molecular entity in trials to treat primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation for both diseases. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.